| Todd Jacob Struckman, MD | |
|
1012 E 2nd St, Duluth, MN 55805-2200 | |
| (218) 249-5555 | |
| Not Available |
| Full Name | Todd Jacob Struckman |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 1012 E 2nd St, Duluth, Minnesota |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316175565 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 55798 (Minnesota) | Primary |
| Entity Name | St Lukes Hospital Of Duluth |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902845068 PECOS PAC ID: 7113834839 Enrollment ID: O20031120000212 |
News Archive
As the leading advocacy, research and support organization for Alzheimer's disease, the Alzheimer's Association commends Representatives Christopher Smith and Edward Markey for their leadership in introducing the Alzheimer's Breakthrough Act (H.R.1897) in the U.S. House of Representatives.
Aduro BioTech, a clinical-stage immunotherapy company, is pleased to announce the presentation of the CRS-207 Phase 1 study at the AACR Special Conference on Tumor Immunology in Miami, Florida by the Principal Investigator, Dr. Dung Le of the Johns Hopkins Kimmel Cancer Center. Dr. Le reported that CRS-207 intravenous administration was well tolerated in subjects with advanced, treatment-refractory cancers. Dr. Le also reported evidence of immune activation and that 6 out of 17 end-stage cancer patients lived 15 months or longer.
Hyperkinetic disorders among children and adolescents are becoming increasingly common. In the current issue of Deutsches Ärzteblatt International, Ingrid Schubert of the PMV Research Group at the University of Cologne and her colleagues address the question how this has affected the frequency of prescriptions for methylphenidate, a stimulant drug that is used to treat such disorders.
InSightec Ltd, the global leader in MR guided focused ultrasound, announced that the first patient has been treated as part of an ExAblate Neuro Phase III pivotal trial. The trial is a multicenter, double-blinded, randomized study to evaluate the efficacy and safety of treatment using the ExAblate Neuro in medication-refractory essential tremor patients.
Chances are good that a medication you take is one of several drugs that can be affected by genetic factors, according to researchers at Washington University School of Medicine in St. Louis and the St. Louis College of Pharmacy.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Todd Jacob Struckman, MD 915 E 1st St, Duluth, MN 55805-2107 Ph: (218) 249-5616 | Todd Jacob Struckman, MD 1012 E 2nd St, Duluth, MN 55805-2200 Ph: (218) 249-5555 |
News Archive
As the leading advocacy, research and support organization for Alzheimer's disease, the Alzheimer's Association commends Representatives Christopher Smith and Edward Markey for their leadership in introducing the Alzheimer's Breakthrough Act (H.R.1897) in the U.S. House of Representatives.
Aduro BioTech, a clinical-stage immunotherapy company, is pleased to announce the presentation of the CRS-207 Phase 1 study at the AACR Special Conference on Tumor Immunology in Miami, Florida by the Principal Investigator, Dr. Dung Le of the Johns Hopkins Kimmel Cancer Center. Dr. Le reported that CRS-207 intravenous administration was well tolerated in subjects with advanced, treatment-refractory cancers. Dr. Le also reported evidence of immune activation and that 6 out of 17 end-stage cancer patients lived 15 months or longer.
Hyperkinetic disorders among children and adolescents are becoming increasingly common. In the current issue of Deutsches Ärzteblatt International, Ingrid Schubert of the PMV Research Group at the University of Cologne and her colleagues address the question how this has affected the frequency of prescriptions for methylphenidate, a stimulant drug that is used to treat such disorders.
InSightec Ltd, the global leader in MR guided focused ultrasound, announced that the first patient has been treated as part of an ExAblate Neuro Phase III pivotal trial. The trial is a multicenter, double-blinded, randomized study to evaluate the efficacy and safety of treatment using the ExAblate Neuro in medication-refractory essential tremor patients.
Chances are good that a medication you take is one of several drugs that can be affected by genetic factors, according to researchers at Washington University School of Medicine in St. Louis and the St. Louis College of Pharmacy.
› Verified 3 days ago
Blake Ervin Collison, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 407 E 3rd St, Duluth, MN 55805 Phone: 218-786-4000 | |
Dr. Gregory K Bernhardt, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 915 E 1st St, Duluth, MN 55805 Phone: 218-249-5616 | |
Dr. Colton David Wiesner, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 402 E 2nd St, Duluth, MN 55805 Phone: 218-786-4000 | |
Dr. Wendell Rhett Bonner, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 4212 Grand Ave, Duluth, MN 55807 Phone: 218-786-3500 | |
Dr. Erika M Miles, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 407 East 3rd Street, St. Mary's Medical Center, Duluth, MN 55805 Phone: 218-786-4357 | |
Dr. Timothy E Borden, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 400 East Third Street, Essentia Health Duluth Clinic, Duluth, MN 55805 Phone: 218-786-8364 | |
Dr. Dalton Grimm, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 915 E 1st St, Duluth, MN 55805 Phone: 218-249-5555 |